Clinical Trial Update: OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating immune checkpoint inhibitor, capecitabine, or their combination as adjuvant therapy for triple-negative breast cancer with residual dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Georgetown University | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-12-03